|
|
Article: United States : Aduro BioTech raises funds through its Series A-1 financing.
- Article from:
- TendersInfo
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 Al Bawaba (Middle East) Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: pinto03
Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing. Individual investors, including senior management of the company, provided a $2 million equity round. Aduro has also secured an additional $2.7 million in funding through grants and contracts from the Department of Defense for development of a therapeutic vaccine for Hepatitis C, and from the National Institute of Allergy and Infectious Diseases (via the University of New Mexico) for the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Robin Jones Marketing changes firm name to Aduro.
Frederick News-Post (Frederick, MD);
September 28, 2007 ;
600 words
... ... Robin Jones Marketing on Monday became Aduro. According to a press release, the decision ... said Ellie Whims, managing partner for Aduro, in a statement. "We were looking for ... and creative excellence to remain." Why Aduro? It's the Latin name for "to kindle ...
|
|